Today: 17 October 2025
Subscribe
Femasys (FEMY) Stock Soars 46% on Fertility Tech and FDA Milestones
 ·  ·  ·  · 

Femasys (FEMY) Stock Soars 46% on Fertility Tech and FDA Milestones

by
16 October 2025
  • Stock action: Femasys (NASDAQ: FEMY) jumped roughly 46% on Oct. 16, 2025, trading around $0.80 by mid-day [1] [2]. (Previous close: $0.55). This spike followed news of the company’s upcoming fertility trade-show exhibition and broader industry catalysts.
  • Key event: Femasys will exhibit at ASRM 2025 (Oct 25–29) in San Antonio, showcasing its new FemaSeed® Intratubal Insemination fertility treatment [3]. CEO Kathy Lee-Sepsick said, “We are excited to return to ASRM to share our next-generation… FemaSeed® Intratubal Insemination,” underlining the company’s focus on reproductive therapies [4].
  • Regulatory wins – FemBloc®: Femasys’ non-surgical birth control device FemBloc won key approvals in 2025. It received a CE Mark in Europe (June 2025), MHRA approval in the UK (Aug 2025) [5], and MEDSAFE approval in New Zealand (Sept 2025) [6]. These endorsements make FemBloc the first in-office, non-surgical permanent birth control available in those regions.
  • First sales & partnerships: Following EU approval, Femasys sold its first European order (~$400,000) of FemBloc to Spanish partners in mid-2025 [7]. In late Sept. the company announced a partnership with Kebomed to distribute FemBloc in France and Benelux [8], further opening the largest European markets. Globally, new fertility product partnerships were also struck: in Sept. Femasys teamed with Medical Electronic Systems (MES) to launch a FemSperm™ Analysis Kit – completing its suite of in-office sperm-prep tools for FemaSeed treatment [9]. (In August it debuted the FemSperm Setup Kit and Prep Kit for gynecologists.)
  • Other developments: Earlier this year Femasys announced Australian/New Zealand approvals for its FemaSeed infertility product and FemVue diagnostic [10], and a U.S. clinic partnership (Carolinas Fertility Institute) to roll out FemaSeed at eight locations [11]. In August it priced an $8.0 million stock financing to fund commercialization [12] (closing soon after) and reported Q2 2025 revenue of $0.409M (+85% YoY) with a smaller-than-expected net loss ($0.16/share vs. –$0.18 est.) [13].

Femasys’ stock surge on Oct. 16 mirrors growing investor interest in its reproductive healthcare pipeline. The company’s FemaSeed™ technology is designed to boost pregnancy rates by delivering sperm directly into the fallopian tube, and published trials report more than double the pregnancy rate of traditional intrauterine insemination [14] [15]. Femasys is positioning FemaSeed as a first-line, lower-cost infertility option ahead of IVF. Meanwhile, FemBloc offers a first-of-its-kind permanent birth control that creates a natural scar in the fallopian tubes, avoiding surgery [16] [17].

This week’s ASRM announcement – coinciding with broader fertility news – helped lift FEMY. Also on Oct. 16, national media reported an expected US policy to expand IVF access, which analysts say has indirectly boosted Femasys’ profile. By midday on Oct. 16, FEMY was up about 46% at roughly $0.80 [18] [19] (well above its 52-week low ~$0.31 [20]). (Intraday, GuruFocus.com noted a 30% jump to $0.72 amid the IVF news, reflecting high volatility.)

Financials: Femasys is still unprofitable with a small market cap (~$30M) and past-year losses. In Q2 2025 it reported $0.41M sales (vs. $0.22M year-ago) and a net loss of $4.59M (−$0.16/share), about flat with 2024 [21]. Cash on hand was only $3.2M at Q2-end, though the recent $8M financing (Aug) will extend its runway [22]. The company expects this funding to “ramp commercialization of our FemaSeed® and FemBloc® offerings” [23].

Analyst views: Wall Street opinions are mixed. Online consensus remains bullish: for example, StockAnalysis.com shows a “Strong Buy” consensus and an average 12-month target of $7.33 (an 800%+ upside from current levels) [24]. TipRanks similarly cites an average target of about $3.83 (≈550% upside) [25]. By contrast, Weiss Ratings in early Oct. reiterated a “Sell (E+)” grade on FEMY [26]. MarketBeat notes that 3 analysts rate Femasys a Buy and 1 a Sell, giving an overall “Moderate Buy” consensus [27]. HC Wainwright (a regular coverage firm) last week trimmed its target to $8.00 (from $12) but kept a Buy rating [28].

In summary, Femasys is trading on recent product and regulatory progress. The stock’s Oct. 16 rally reflects excitement over its fertility-technology milestones (IVF-related news and ASRM expo) [29] [30]. However, analysts caution that the company still faces financial challenges (high losses, funding needs) [31]. Looking ahead, key watchpoints include further FDA updates (the pivotal “FINALE” trial for FemBloc is enrollingpatients [32] [33]), upcoming sales of FemBloc in Europe, and Femasys’ Q3 results. For now, price targets range widely. As one analyst summary put it, investors are weighing Femasys’ “next-generation infertility innovation” against its cash burn and market risks [34] [35].

Sources: Femasys press releases and SEC filings [36] [37]; Market data from Investing.com and MarketBeat [38] [39]; analyst reports (MarketBeat, StockAnalysis, TipRanks) [40] [41] [42]; industry news outlets.

References

1. www.marketbeat.com, 2. www.investing.com, 3. www.globenewswire.com, 4. www.globenewswire.com, 5. ir.femasys.com, 6. ir.femasys.com, 7. ir.femasys.com, 8. ir.femasys.com, 9. www.stocktitan.net, 10. ir.femasys.com, 11. ir.femasys.com, 12. www.stocktitan.net, 13. ir.femasys.com, 14. www.globenewswire.com, 15. www.stocktitan.net, 16. ir.femasys.com, 17. ir.femasys.com, 18. www.marketbeat.com, 19. www.investing.com, 20. www.investing.com, 21. ir.femasys.com, 22. www.stocktitan.net, 23. www.stocktitan.net, 24. stockanalysis.com, 25. www.tipranks.com, 26. www.americanbankingnews.com, 27. www.americanbankingnews.com, 28. www.americanbankingnews.com, 29. www.globenewswire.com, 30. www.marketbeat.com, 31. www.gurufocus.com, 32. www.globenewswire.com, 33. ir.femasys.com, 34. www.globenewswire.com, 35. www.americanbankingnews.com, 36. ir.femasys.com, 37. ir.femasys.com, 38. www.marketbeat.com, 39. www.investing.com, 40. www.americanbankingnews.com, 41. stockanalysis.com, 42. www.tipranks.com

Tags:

Marcin Frąckiewicz Latest posts

CEO of TS2 Space and founder of TS2.tech. Expert in satellites, telecommunications, and emerging technologies, covering trends in space, AI, and connectivity.

  1. GitLab Stock Soars 11% on Datadog Takeover Rumors Amid AI DevOps Boom
  2. Praxis Precision Medicines (PRAX) Stock Skyrockets 180% on Game‑Changing Trial – Analysts See ‘Blockbuster’ Upside
  3. CSX Delivers Earnings Surprise: Stock Jumps as New CEO Navigates Rail Merger Frenzy
  4. Interactive Brokers Stock Soars After Q3 Earnings Beat, 40% Asset Surge

Related Articles

Beyond Meat Stock CRASH: 60% Plunge After Shocking Debt Swap Stuns Investors
Previous Story

Beyond Meat Shares Plunge as Debt Restructure Sparks Panic

Up 150% YTD: Navitas Semiconductor (NVTS) Rides the GaN Power Wave into AI’s Future
Next Story

Navitas (NVTS) Stock Hits All-Time High on NVIDIA AI Chip News – Will the Rally Continue?

Stock Market Today

  • Centerspace (CSR) Crosses Above 200-Day Moving Average
    October 17, 2025, 3:37 AM EDT. Centerspace (CSR) shares surged on Thursday as they crossed above the 200-day moving average near $60.64, trading as high as $61.16. The stock was up about 1.5% on the session. The move comes as CSR trades around $60.75 after testing the 52-week range, which spans from $52.76 to $75.92. Analysts and traders watch for a sustained close above the 200-day moving average, which could signal renewed bullish momentum. The chart highlights a one-year view of CSR relative to its long-term trend, with current price positioning sitting above the recent consolidation but below the 52-week high.
  • Centerspace CSR Crosses Above 200-Day Moving Average
    October 17, 2025, 3:35 AM EDT. Centerspace (CSR) shares rose above their 200-day moving average of $60.64 on Thursday, hitting as high as $61.16 and trading about 1.5% higher on the session. The chart shows CSR's one-year performance relative to the 200-day moving average. The stock's 52-week range runs from $52.76 to $75.92; the last trade was $60.75, placing it just above the benchmark.
  • Centerspace (CSR) Crosses Above 200-Day Moving Average, Intraday High $61.16
    October 17, 2025, 3:33 AM EDT. Centerspace (CSR) shares crossed above their 200-day moving average of $60.64 on Thursday, trading as high as $61.16 and last seen around $60.75. The stock is up about 1.5% for the session. This break above the 200-day moving average can be interpreted as a near-term bullish signal as CSR moves within its one-year performance context. The stock's 52-week range is $52.76 to $75.92, highlighting upside and downside potential. If today's move sustains, traders will be watching for continued momentum and whether CSR can push toward or beyond the next resistance level.
  • Centerspace (CSR) Breaks Above 200-Day Moving Average on Strong Session
    October 17, 2025, 3:31 AM EDT. Centerspace (CSR) shares jumped to near session highs after crossing above the 200-day moving average of $60.64. The stock traded as high as $61.16 and was about 1.5% higher on the day, with the last trade at $60.75. The move comes as CSR tests the one-year pattern against its long-term trend, with the 52-week range spanning $52.76 to $75.92. Analysts and traders will watch whether the break above the 200 DMA can sustain momentum and lift the shares toward the next resistance level around the recent highs. The chart shows CSR's performance relative to its 200-day benchmark over the past year.
  • Centerspace (CSR) Breaks Above 200-DMA, Trading Near $61
    October 17, 2025, 3:29 AM EDT. Centerspace (CSR) cleared its 200-day moving average of $60.64 on Thursday, trading as high as $61.16. The stock was up about 1.5% on the session and last traded around $60.75. The move places CSR near the top of its one-year chart versus the 200-DMA. Over the past year, CSR has traded between a 52-week low of $52.76 and a 52-week high of $75.92. The development may be read as a potential bullish signal, though no assurances accompany moving-average crosses. Investors often watch such crossings for trend confirmation. Analysts and traders should consider other indicators and fundamentals before making decisions.
Go toTop